The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

被引：0
作者：
Chiao-En Wu
Chan-Keng Yang
Meng-Ting Peng
Pei-Wei Huang
Ching-Fu Chang
Kun-Yun Yeh
Chun-Bing Chen
Chih-Liang Wang
Chao-Wei Hsu
I-Wen Chen
Cheng-Tao Lin
Shir-Hwa Ueng
Gigin Lin
Yu-Fen Lin
Chi-Yuan Cheng
John Wen-Cheng Chang
机构：
[1] Chang Gung Memorial Hospital,Division of Haematology
[2] Chang Gung University College of Medicine,Oncology, Department of Internal Medicine
[3] Chang Gung Memorial Hospital at Linkou,Immuno
[4] Chang Gung Memorial Hospital,Oncology Center of Excellence
[5] Chang Gung University College of Medicine,Division of Hemato
[6] Chang Gung Memorial Hospital at Linkou,Oncology, Department of Internal Medicine
[7] Chang Gung Memorial Hospital,Department of Dermatology
[8] Chang Gung Memorial Hospital,Department of Thoracic Medicine
[9] Chang Gung Memorial Hospital,Department of Gastroenterology and Hepatology
[10] ,Division of Endocrinology and Metabolism, Department of Internal Medicine
[11] Chang Gung Memorial Hospital,Department of Obstetrics and Gynecology
[12] Chang Gung Memorial Hospital,Department of Pathology
[13] Chang Gung Memorial Hospital,Department of Medical Imaging & Intervention
[14] Chang Gung Memorial Hospital,Department of Nursing
[15] ,Department of Pharmacy
[16] Chang Gung Memorial Hospital,undefined
来源：
BMC Cancer | / 20卷
关键词：
Immune checkpoint inhibitors; irAE; Skin toxicity; Vitiligo; Endocrine; Melanoma; PD-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 226 条
[1]  
Hodi FS(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711-723
[2]  
O'Day SJ(2018)Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Lancet Oncol 19 1480-1492
[3]  
McDermott DF(2019)Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Ann Oncol 30 582-588
[4]  
Weber RW(2019)Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma N Engl J Med 381 1535-1546
[5]  
Sosman JA(2017)Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma N Engl J Med 377 1345-1356
[6]  
Haanen JB(2016)Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Lancet Oncol 17 1558-1568
[7]  
Gonzalez R(2019)Evaluation of two dosing regimens for Nivolumab in combination with Ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial J Clin Oncol 37 867-875
[8]  
Robert C(2019)Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors J Immunother Cancer 7 306-67
[9]  
Schadendorf D(2019)Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with Nivolumab: a multicenter retrospective study Clin Ther 41 59-27
[10]  
Hassel JC(2019)Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients Eur J Cancer 109 21-207
12345678910